Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Baseline and early changes in neutrophil-lymphocyte ratio as a prognostic biomarker with 177Lu-PSMA-617 therapy in advanced prostate cancer.

Created on 15 Nov 2026

Authors

Ronit Juthani, Caiwei Zhong, Ali Tarhini, Miguel Muniz, Wanling Xie, Hailey Stoltenberg, Andrew Wolanski, Jolivette Ritzer, Xiao X Wei, Heather Jacene, Daniel S Childs, Praful Ravi

Published in

Prostate cancer and prostatic diseases. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

The prognostic impact of neutrophil-lymphocyte ratio (NLR) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC) is unclear.
This was a retrospective analysis of 501 patients receiving LuPSMA for mCRPC post-taxane across two institutions between 2022 and 2024.
NLR > 3 at cycle 1 was an independent predictor of poorer survival, and patients with NLR > 3 at cycle 1 and cycle 2 had the poorest outcomes.
NLR > 3 is an adverse prognostic factor in patients receiving LuPSMA, and early NLR dynamics may be helpful in identifying patients who require closer disease monitoring during therapy.

PMID:
43034183
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement